Home >> NVP-TNKS656
Related Products
NVP-TNKS656 TNKS2 inhibitor

Catalog No.B6046
Size Price Stock Qty
10mM (in 1mL DMSO)
$390.00
In stock
5mg
$359.00
In stock
10mg
$624.00
In stock
25mg
$1,076.00
In stock
50mg
$1,872.00
In stock
100mg
$2,808.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

      

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

NVP-TNKS656

NVP-TNKS656 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

NVP-TNKS656 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 1419949-20-4 SDF Download SDF
Chemical Name N-(cyclopropylmethyl)-N-((4-hydroxy-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)methyl)-2-(4-(4-methoxybenzoyl)piperidin-1-yl)acetamide
Canonical SMILES COC1=CC=C(C(C2CCN(CC(N(CC3=NC4=C(C(O)=N3)COCC4)CC5CC5)=O)CC2)=O)C=C1
Formula C27H34N4O5 M.Wt 494.58
Solubility Soluble in DMSO Storage Store at -20°C
Physical Appearance A crystalline solid Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Background

NVP-TNKS656 is an orally active antagonist of Wnt pathway activity. The Wnt pathway has been involved in controlling numerous developmental processes. Dysfunction of this pathway may result in carcinogenesis [1].

In vitro: The IC50 value of NVP-TNKS656 against PARP1, TNKS2, PARP2, and STF was > 19, 0.006, 32, and 0.0035 µM, respectively [1].

In vivo: The clearance and volume of distribution of NVP-TNKS656 were 10 mL/min/kg and 0.6 L/kg after intravenous administration in mice. The exposure and oral bioavailability was 32% and 53%, respectively. In the mouse mammary tumor virus (MMTV)-Wnt1 transgenic model, oral administration of NVP-TNKS656 (350 mg/kg) activated the Wnt signaling over a 24-h time course. NVP-TNKS656 treatment reduced the Wnt/beta-catenintarget gene Axin2 mRNA level by 70-80% [1].

Reference:
Shultz M D, Cheung A K, Kirby C A, et al.  Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor[J]. Journal of medicinal chemistry, 2013, 56(16): 6495-6511.